Anti-T170B/ ™EM170B monoclonal antibody

Anti-T170B/ ™EM170B antibody for FACS & in-vivo assay

Target products collectionGo to ™EM170B/™EM170B products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdfMSDSpdfCOApdfDatasheet

Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-MP1822-Ab-1/ GM-Tg-hg-MP1822-Ab-2Anti-Human ™EM170B monoclonal antibodyHuman
GM-Tg-rg-MP1822-Ab-1/ GM-Tg-rg-MP1822-Ab-2Anti-Rat ™EM170B monoclonal antibodyRat
GM-Tg-mg-MP1822-Ab-1/ GM-Tg-mg-MP1822-Ab-2Anti-Mouse ™EM170B monoclonal antibodyMouse
GM-Tg-cynog-MP1822-Ab-1/ GM-Tg-cynog-MP1822-Ab-2Anti-Cynomolgus/ Rhesus macaque ™EM170B monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-MP1822-Ab-1/ GM-Tg-felg-MP1822-Ab-2Anti-Feline ™EM170B monoclonal antibodyFeline
GM-Tg-cang-MP1822-Ab-1/ GM-Tg-cang-MP1822-Ab-2Anti-Canine ™EM170B monoclonal antibodyCanine
GM-Tg-bovg-MP1822-Ab-1/ GM-Tg-bovg-MP1822-Ab-2Anti-Bovine ™EM170B monoclonal antibodyBovine
GM-Tg-equg-MP1822-Ab-1/ GM-Tg-equg-MP1822-Ab-2Anti-Equine ™EM170B monoclonal antibodyEquine

Size： 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-MP1822-Ab-1/ GM-Tg-hg-MP1822-Ab-2; GM-Tg-rg-MP1822-Ab-1/ GM-Tg-rg-MP1822-Ab-2;
GM-Tg-mg-MP1822-Ab-1/ GM-Tg-mg-MP1822-Ab-2; GM-Tg-cynog-MP1822-Ab-1/ GM-Tg-cynog-MP1822-Ab-2;
GM-Tg-felg-MP1822-Ab-1/ GM-Tg-felg-MP1822-Ab-2; GM-Tg-cang-MP1822-Ab-1/ GM-Tg-cang-MP1822-Ab-2;
GM-Tg-bovg-MP1822-Ab-1/ GM-Tg-bovg-MP1822-Ab-2; GM-Tg-equg-MP1822-Ab-1/ GM-Tg-equg-MP1822-Ab-2
Products NameAnti-™EM170B monoclonal antibody
Formatmab
Target Name™EM170B
Protein Sub-locationTransmembrane Protein
Category of antibodyFACS/Biofunctional Antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)		IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD).
TagFc
Products descriptionPre-made anti-™EM170B benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    Target AntigenProducts DevelopingMulti-species T170B/ ™EM170B VLP (virus-like particle) (Products Developing)


    Target information

    Target IDGM-MP1822
    Target Name™EM170B
    Gene ID100113407,621976,361230,699495,609876,101091194,101906104,100063959
    Gene Symbol and SynonymsEG621976,™EM170B
    Uniprot AccessionQ5T4T1,Q7TQ79
    Uniprot Entry NameT170B_HUMAN,T170B_RAT
    Protein Sub-locationTransmembrane Protein
    Category
    DiseaseN/A
    Gene EnsemblENSG00000205269
    Target ClassificationN/A

    The target: ™EM170B, gene name: ™EM170B, also named as . Involved in negative regulation of canonical Wnt signaling pathway. Located in plasma membrane. [provided by Alliance of Genome Resources, Apr 2022].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.